Drug Profile
Dasatinib - Bristol-Myers Squibb
Alternative Names: BMS-354825; SprycelLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; City of Hope National Medical Center; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
- Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase III Prostate cancer
- Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
- Phase I/II Glioblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Phase I Malignant-mesothelioma; Waldenstrom's macroglobulinaemia
- No development reported Colorectal cancer; Leukaemia; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer
- Discontinued Pancreatic cancer; Scleroderma
Most Recent Events
- 31 Oct 2022 Dasatinib is still in phase I trials for Mesothelioma in USA (NCT00652574)
- 11 Oct 2022 Bristol-Myers Squibb completes a phase II trial in Chronic myeloid leukaemia and acute lymphoblastic leukaemia (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT00529763)
- 07 Oct 2022 Bristol-Myers Squibb and M. D. Anderson Cancer Center, the Department of Defense completes a phase I trial for Malignant mesothelioma (First-line therapy, Early-stage disease, Mid-stage disease) in USA (NCT00652574)